Gilead’s $11 Billion Gambit – Wall Street Journal
 International Business Times |
Gilead's $ 11 Billion Gambit
Wall Street Journal In 4 pm trading Monday on the Nasdaq Stock Market, Pharmasset shares were up 85% at $ 134.14. An estimated four million Americans have hepatitis C, but only about a million of them have been diagnosed. Most victims go untreated rather than endure weekly … Pre-Market NASDAQ Movers (GEDU, VRUS, BSDM, LOOP, CLDX, NLST, GILD, MPEL, CEDC … Gilead bets $ 11 billion on hepatitis in Pharmasset deal, (NASDAQ: GILD), (NYSE … Market Volatility = Biotech Opportunity |
